Cargando…

Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer

PURPOSE: Everolimus is a novel inhibitor of the mammalian target of rapamycin pathway, which is aberrantly activated in cancer cell. We conducted a phase I study of capecitabine plus everolimus (RAD001) in refractory gastric cancer patients. METHODS: Patients with metastatic gastric cancer and progr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Taekyu, Lee, Jeeyun, Lee, Duk Joo, Lee, Ha Yeon, Han, Boram, Baek, Kyung Kee, Ahn, Hee Kyung, Lee, Su Jin, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kim, Kyoung-Mee, Kang, Won Ki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2011
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123695/ https://www.ncbi.nlm.nih.gov/pubmed/21526353 http://dx.doi.org/10.1007/s00280-011-1653-5

Ejemplares similares

To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients
por: Lee, Hansang, et al.
Publicado: (2016)

Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
por: Kim, Seung Tae, et al.
Publicado: (2016)

NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer
por: Das, Kakoli, et al.
Publicado: (2016)

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy
por: Kim, Seung Tae, et al.
Publicado: (2017)

Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review
por: Agarwala, Sanjiv S., et al.
Publicado: (2010)

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
por: Barrios, Carlos H., et al.
Publicado: (2010)

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma
por: Huynh, Hung, et al.
Publicado: (2009)

Changes in the Mean Corpuscular Volume after Capecitabine Treatment Are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer
por: Jung, Hyun Ae, et al.
Publicado: (2015)

A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer
por: Jo, Hyunji, et al.
Publicado: (2023)

Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression
por: Park, Ji Hyun, et al.
Publicado: (2015)

Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial
por: Kim, Seung Tae, et al.
Publicado: (2019)

Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
por: Park, In Hae, et al.
Publicado: (2019)

Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation
por: Lee, Taehyang, et al.
Publicado: (2018)

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
por: Saura, Cristina, et al.
Publicado: (2021)

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial
por: Park, Junsik, et al.
Publicado: (2021)

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
por: Kim, Seung Tae, et al.
Publicado: (2014)

Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes
por: Lim, Taekyu, et al.
Publicado: (2011)

Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
por: Dai, Ming Shen, et al.
Publicado: (2021)

Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells
por: Tai, Sheng, et al.
Publicado: (2017)

Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma
por: Park, Se Hoon, et al.
Publicado: (2006)

Oxaliplatin-Induced Chronic Peripheral Neurotoxicity: A Prospective Analysis in Patients with Colorectal Cancer
por: Baek, Kyung Kee, et al.
Publicado: (2010)

Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2
por: Beck, J. Thaddeus, et al.
Publicado: (2013)

Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial
por: Park, Se Hoon, et al.
Publicado: (2005)

Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors
por: Okamoto, Isamu, et al.
Publicado: (2010)

Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib
por: Juengel, Eva, et al.
Publicado: (2015)

Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study
por: Lee, Su Jin, et al.
Publicado: (2015)

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
por: Marth, Christian, et al.
Publicado: (2022)

The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells
por: Kuwatsuka, Y, et al.
Publicado: (2011)

Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1
por: Alshaker, Heba, et al.
Publicado: (2016)

Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08‐20
por: Patt, Yehuda, et al.
Publicado: (2017)

The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC)
por: Heo, Mi Hwa, et al.
Publicado: (2017)

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
por: Kim, Seung Tae, et al.
Publicado: (2021)

An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients
por: Lee, Ji Yun, et al.
Publicado: (2017)

Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan
por: Lee, Sung Uk, et al.
Publicado: (2013)

The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer
por: Kim, Seung Tae, et al.
Publicado: (2018)

A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer
por: Lolli, Cristian, et al.
Publicado: (2017)

A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma
por: Changou, Chun A., et al.
Publicado: (2020)

Hepatectomy Followed by Adjuvant Chemotherapy with 3‐Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases
por: Satake, Hironaga, et al.
Publicado: (2021)

Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane
por: Ahn, Jin-Hee, et al.
Publicado: (2004)

A comparison of the quality assurance of four dosimetric tools for intensity modulated radiation therapy
por: Son, Jaeman, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_a31a9g3c2qj97jh9hhps3o3jpo